Open access

Insights to the Ethiopathogenesis of the Inflammatory Bowel Disease

Written By

Ana Brajdić and Brankica Mijandrušić-Sinčic

Submitted: May 19th, 2012 Published: December 5th, 2012

DOI: 10.5772/52970

Chapter metrics overview

1,968 Chapter Downloads

View Full Metrics

1. Introduction

Inflammatory bowel disease (IBD) is a term that refers to two very different yet in many ways related phenotypes, Crohn’s disease (CD) and ulcerative colitis (UC). It is well known that both of the two primary human inflammatory bowel diseases are characterized by chronic inflammation of the intestinal tract, yet their etiology still remains unclear.

CD and UC are considered to be multifactorial diseases and the underlying pathological process seems to be a combination of genetic predisposition and immunologic disturbances. Being the largest surface in the human body and since it is constantly colonized by a highly diverse community of microbes that are in normal circumstances either commensal or beneficial to human health, the role of the intestinal microbiota in development of IBD has been thoroughly investigated over the years. It is now generally accepted that the commensal flora plays a central role in triggering and perpetuating the disease process. [1] Even though there are several logical arguments contributing to the theory that the intestinal microbiota plays a major role in the IBD development, the types of microbes involved have not been adequately described. Studies of experimental animal models of IBD uncover that the presence of gut bacteria is essential in inflammation initiation and there is no disease onset in germ-free mice [2]. Furthermore, decreasing bacterial numbers in the intestine by using antibiotics, can lead to clinical improvement and decreased inflammation in both humans [3] and animal models of IBD [4, 5].

Pathogenesis of the IBD is characterized by various genetic abnormalities that lead to overly aggressive altered immune response, triggered by heterogeneous environmental factors under the influence of the commensal intestinal microbiota. There is no single abnormality of the gastro intestinal tract that would lead to development of CD or UC. Only in correlation of those four mentioned main factors a dysbalance of the gastrointestinal tract develops, leading to chronic inflammation with all its consequences and complications. Schematized and simplified pathogenesis involving correlation between environmental factors, genetic predisposition, host immune response and intestinal microbiota is shown in Figure 1.

Figure 1.

Schematized correlation of main factors involved in the IBD pathogenesis. Each of the mentioned factors fit together as separate pieces of puzzle, together creating a complex clinical and pathological image of the IBD.

In this review, we discuss recent insights in the ethiopathogenesis of the inflammatory bowel diseases.


2. Etiology and pathophysiology

2.1. Environmental factors

Epidemiological studies show that the prevalence of IBD dramatically increased in northern Europe, the United Kingdom and North America in the second half of the twentieth century and is also increasing in the rest of the world, proportionally to the adoption of western lifestyle [6]. This process, known as “westernization” of lifestyle [7], includes environmental triggers such as smoking (shown to be protective in UC but detrimental in CD), use of antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs), stress, infection and diet. Studies have also reported an association between early life exposure to antibiotics (in the first year of subject’s life) and CD development due to early childhood dysbiosis [8].

The mechanisms by which these factors initiate the onset of IBD are still not well understood. There is some evidence that infection and NSAIDs can transiently initiate nonspecific inflammation, break the mucosal barrier and activate innate immune response [9]. This process may lead to enhanced uptake of commensal bacterial antigens and in combination with genetic susceptibility, in this way stimulate protracted T-cell mediated inflammation. Up until now, only smoking and appendectomy have been clearly linked with the risk of developing IBD. A recent cohort study concerning autophagy-related genes and granuloma formation in surgically treated CD patients has showed that there is a significant association between smoking and granuloma formation [10]. This observation could be a result of inflammation promoting effects of smoking, resulting in more severe inflammation with granulomas in smokers with CD [10]. Appendectomy and smoking reduce risk for UC but on the other hand, active smoking increases risk for CD [11]. Even though proven to be valid, these facts cannot be held answerable for all variations in IBD incidence and prevalence.

There is also a hypothesis known as the “hygiene hypothesis”, that could be the fundamental reason for the switch from infectious to chronic inflammatory diseases. This hypothesis proposes that there has been a lifestyle change from one with high microbial exposure to one with low microbial exposure [12]. There are numerous environmental factors that could be assigned to the hygiene hypothesis, some of which being better housing, safer food, cleaner water, vaccines, dietary changes, fewer infections, improved hygiene and sanitation and widespread use of antibiotics [12].

Even though there are many firm epidemiological studies and evidence linking certain environmental factors to greater probability of developing IBD, it is still widely believed that there is no one simple environmental factor that could alone cause CD or UC. Based on the fact that differences in geographic distribution combined with changes in incidence over time within one observed area could provide insights into possible etiologic factors, a prospective population based study investigated the incidence of UC and CD in Primorsko-goranska County, Croatia (January 2000 to December 2004) was performed by the authors [13]. The study included a total of 170 patients residing a county with a stable, ethnic and racially homogeneous population and the results showed an increase in UC and CD incidence, in comparison to an earlier prospective study for the county of Zagreb, with a similar population and similar environmental circumstances [13]. It is considered that the rapid “westernization” of the country combined with the improved awareness of the disease play a role in the reported increase. Annual age-standardized incidence rate was 4,3/105 for UC and 7,0/105 for CD. Croatian results concerning UC were similar to those reported in Belgium, Northern France and Germany and those concerning CD reach the mean incidence value reported in European multicentric study of CD [13].

2.2. Genetic predisposition

There have recently been great advances in understanding the very complex genetics of the IBD, from studies based on single nucleotide polymorphism and candidate gene approaches to studies based on transgenic and deletion techniques [14]. It is thought that UC and CD may be heterogeneous polygenic disorders, sharing some but not all susceptibility loci and there are most likely several factors determining the disease phenotype [15]. Presence of a mutated gene in a host does not guarantee that IBD will develop and we cannot use it as a predicting factor for later development of IBD.

In order to prove that genetic factors contribute to the pathogenesis of IBD, studies have shown that the concordance rate between twins is much lower for UC than for CD, which may indicate that the genetic penetrance in CD is much greater than in UC. Reported concordance rate for UC in monozygotic twins is 15,4% vs. 3,9% in dizygotic twins and for CD 30,3% in monozygotic vs. 3,6% in dizygotic twins [16]. These findings may be considered valuable evidence that there is genetic susceptibility for IBD, particularly CD. Also, studies have shown that there is linkage between certain genetic disorders and incidence of IBD. In infants born to consanguineous parents there is a risk of developing extremely rare autosomal recessive mutations in genes encoding interleukin (IL)-10 receptor and the IL-10 cytokine [17, 18]. IL-10 is an anti-inflammatory cytokine and its primary purpose is to limit and ultimately terminate inflammatory responses [19]. Disturbance in either IL-10 or IL-10 receptor function via autosomal, recessive mutations are sufficient to cause severe forms of CD, which have been successfully treated by bone marrow transplantation [20].

There have been over a hundred IBD genes and loci defined and one of the most important genes associated with CD is nucleotide binding oligomerization domain protein 2 (NOD 2), also known as the caspase recruitment domain family member 15 (CARD15) gene [21, 22]. The NOD2 gene is expressed mainly in monocyte/macrophage cell lines where it plays an important role in host-signaling pathways. One of its main effects is the activation of the NF-κB protein, a transcription factor involved in cellular inflammatory pathways and an important regulator in cell fate decisions, such as programmed cell death and proliferation control, and also a critical factor in tumorigenesis.

The NOD2 mutations have been observed in individuals of European and African-American ancestry and studies have shown that in individuals of European ancestry heterozygous carriage of one of the major risk alleles bargain a 2,4-fold increase in risk for CD while homozygous or compound heterozygous carriage bargains 17,1-fold increase in risk for CD [22]. In those of African American origin, mutations are only heterozygous with similar risk for CD among carriers as mentioned above. When it comes to Asian populations, studies show that NOD2 mutation has not been associated with CD in studies of IBD patients form Hong Kong, China, Japan and Korea [23]. Mutations in the NOD2 gene, unexpectedly, reduce macrophage activation of NF- κB protein, which is why one would expect inflammation to weaken, instead of the increase of inflammation, which can be seen in IBD. In the absence of NOD-2 expression by epithelial cells, microbial products that normally induce these cells to secrete chemokines fail to do so, leading to potential loss of barrier function [7].

It is known that in about 70% of patients suffering from CD, the disease affects the small intestine. The human intestinal epithelial wall exceeds all other tissues of the human organism in its cell-renewal rate [24]. The intestinal adult stem cells self-renew and produce daughter cells. Daughter cells form an adjacent zone of rapidly cycling progenitors and undergo 4-6 rounds of division before differentiating into multiple lineages, fabricating up to 300 cells/crypt per day [25]. In this way, post-mitotic cells covering the biggest area of the intestinal epithelium are formed.

Besides absorptive cells, there are three classes of secretory cells: goblet cells (secrete mainly mucus), enteroendocrine cells (secreting different hormones) and Paneth cells [26]. Currently, the most acceptable role of Paneth cells in the small intestine is the production of a stream of antibacterial secretions, responsible for the sterile environment of the small intestinal lumen and in this way, protection of the vital stem cells in the neighborhood. Two most frequent defensins found in Paneth cells are the α defensins, human defensin 5 and 6 (DEFA5 and DEFA6) and in addition to DEFA5 and DEFA6, Paneth cells store several other antibiotic peptides (for example regenerating islet-derived 3-γ and phospholipase A2group IIA) [27]. Investigations on human α defensins have shown that DEFA5 has a very effective antibacterial activity against S. aureus, while DEFA6 expressed some antibacterial potential in vitro and there are ongoing investigations on their antiviral potential [28, 29]. There is numerous evidence for a link between the Paneth cell and ileal Crohn’s disease. It is reported that NOD 2 is heavily expressed in Paneth cells and ileal CD is associated with a diminished synthesis of Paneth cell defensins [30, 31]. The role of NOD2 as an intracellular receptor for bacterial dipeptide in regulating Paneth cell defensin formation was confirmed in NOD-2 knockout mice and in patients after small intestinal transplantation [32, 33].

Being a genetically complex system, pathogenesis of IBD can be closely linked to numerous other genomic regions. Autophagy 16-like 1 (ATG16L1) is responsible for encoding a protein component of the autophagy complex and it has been strongly related to CD [34]. ATG16L1 is extensively expressed, including in Paneth cells, where it has a role in exocytosis of secretory granules containing antimicrobial products [35].

Other genes that regulate autophagy and that have been closely related to CD in genome-wide association studies are immunity-related guanosine triphosphotase M (IRGM) and leucine-rich repeat kinase 2 (LRRK2) [36, 37]. A recent study by Brinar et al. [10] investigated a relationship between variants in autophagy genes and granuloma formation in CD. The authors hypothesized that genetic variants in autophagy genes in CD patients may lead to impaired processing of intracellular bacterial components, thus contributing to granuloma formation. [10]. This cohort study detected an association in four autophagy genes, ATG4A, ATG4D, FNBP1L and ATG2A. The study has also shown that granuloma positive patients were significantly younger at diagnosis, that they had surgery at significantly younger age after a shorter duration of the disease. These findings suggest that there is a significant relationship between earlier mentioned variants in autophagy genes and granuloma formation, which could be a marker of a more aggressive disease course. [10]

After variants in NOD2, most significantly associated with CD is the amino acid change Arg381Gln variant in the IL-23 receptor (IL23). In comparison to Arg381 carriers, Glutamine 381 reduces risk for IBD by nearly 3-fold and studies on the proinflammatory role of IL-23 prioritize its signaling pathway as a therapeutic target in inflammatory bowel disease [38]. Many genes that encode factors in the IL-23 pathway have been associated with both psoriasis and IBD and numerous loci have been associated with both IBD and celiac disease [39, 40]. Studies show that neither IL23 nor ATG16L1 genes are associated with CD in Japanese and Korean patients [41].

There are numerous other loci associated with both CD and UC and the number of potential IBD genes continues to increase and searching for other genotype-phenotype correlations in the matter of IBD continues to be an important step in future studies. Despite all the facts specified, indications for genetic tests in everyday clinical practice still do not exist.

2.3. Host immune response

In order to develop IBD, both innate (macrophage, neutrophil) and acquired (T and B cells) immune responses combined with loss of tolerance to enteric commensal bacteria need to be activated in a host.

2.3.1. Innate immune responses

Studies have shown that there is an increase in the absolute number of macrophages and dendritic cells in both forms of IBD, with an enhanced production of proinflammatory cytokines and chemokines and an increase in the expression of adhesion molecules and co-stimulatory molecules [41].

Adhesion molecules (such as intracellular cell adhesion molecule 1, ICAM1 ) are crucial when it comes to binding circulating cells to the activated endothelium [42]. These molecules also have an important role in later mediation of migration of the extravagated immune cells through the stroma to the source of optimum chemokine production as well as through the epithelium to the lumen [43]. Mucosal dendritic cells are activated, express higher levels of the toll like receptors (TLR) 2 and 4, (which have an important role in recognition of bacterial products) and CD40, all of which is followed by increased production of IL-12 and IL-6 [44]. TLRs are profusely expressed on the surface of monocytes, macrophages, dendritic and epithelial cells and are responsible in identification of the commensal microflora as well as maintenance of the intestinal homeostasis [45]. Like NOD2, they selectively bind to specific microbial adjuvants and initiate signaling through nuclear factor kappa-light-chain-enhancer of activated B cell, NF-κB. Activation of NF-κB triggers expression of various molecules involved in the inflammatory response (such as IL-1β, TNF, IL-6, IL-8, ICAM1, CD 40, CD 80 and other chemokines, adhesion molecules and co-stimulatory molecules), all of which have an increased expression in IBD [41]. NF-κB is activated in tissues of IBD patients and its inhibition can attenuate experimental colitis [46].

In both forms of IBD, alterations of TLR 3 and 4 have been described, suggesting that abnormal bacterial sensing has a role in the disease pathogenesis [47]. As explained earlier, ileal Paneth cells also express the NOD-2 protein, and their production of mucosal α-defensins is decreased in CD patients with NOD-2 mutations.

2.3.2. Adaptive immune responses

Adaptive immune responses should be considered separately for CD and UC, due to their distinct profiles in those two entities. Crohn’s disease

Crohn’s disease is predominantly TH1 and TH17 mediated process. Antigen presenting cells produce IL-12, which is responsible for stimulation of IFN-γ. IFN-γ then mediates traditional TH1 responses. As the inflammatory response matures, in several models TH1 responses can change into TH2 responses [48]. On the other hand, IL-17 mediates TH17 responses [49]. The production of IL-17 is impacted by innate immune cells and antigen presenting cells, which produce Il-6, IL-23 and TGFB [50].

When it comes to estimating the importance between TH1 and TH17 responses in CD development, studies have shown that even though Th17 responses play a role in the inflammation, the Th1 response is quantitatively greater [51]. This conclusion agrees with the intestinal pathologic effects of IFN-γ and the relation of Th1 responses to granulomatous disease [51]. In contribution, double blinded clinical trial of anti IL-17 in patients with CD has been carried out recently and the study showed that blockage of IL-17A is ineffective in tested subjects [51]. The role of IL-17 in patients suffering from CD is still under intense investigation. Ulcerative colitis

Ulcerative colitis is considered to have an atypical TH2 response, mediated by natural killer T cells that secrete IL-13 and IL-5 [52]. The TH2 response is an atypical one due to the fact that concentrations of IL-4 and IL-5, which are normally elevated in TH2 response, have been found to be variable in UC tissues [53]. Recent studies have shown an increase in IL-17 levels in UC (in compare to control groups), but that increase was found to be far less than the one found in CD patients. T-cell subsets are stimulated by antigen presenting cells, particularly dendritic cells, which have a unique capacity to activate naïve T cells. Dendritic cells are found in the lamina propria and Peyer’s patches of normal intestine. Interaction between antigen presenting cells and T cells occurs by presenting an antigen on the surface of the major histocompatibility complex, which is then recognized by the appropriate T-cell receptor, followed by secretion of cytokines ( such as IL-6, IL-10, IL-12, IL-23, TGF β).

The results of this pathway are increased levels of dendritic cells in patients with active IBD and in experimental colitis models [44, 54]. Peyer’s patches, which can be considered as the immune senses of the intestine, seem to play a key organ in the relationship between innate and adaptive immunity in the human gut [55].

2.4. Intestinal microbiota

The understanding of the development of gastrointestinal (GI) tract microbiota has greatly developed, due to decreased costs of DNA sequencing and evolution of bioinformatics.

The human intestinal microbiota can be defined as a community of microbes that is either commensal or beneficial to human health. The adult human gut contains around 1014 bacterial cells and up to a 1000 different bacterial species [56]. The most abundant bacterial phyla in the healthy human large intestine are Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Fusobacteria and Verrucomicrobia [56]. The gut microbiota composition varies between individuals and remains highly stable over time. A recent study performed by Arumugam et al. combined 22 newly sequenced faecal metagenomes of individuals from Denmark, France, Italy and Spain, resulting in three distinctive enterotypes. Furthermore, these results were combined with existing gut data-sets, 13 Japanese and four American, returning the same three clusters. These isolated bacterial communities were dominated by one of the three main distinct bacterial genera – Bacteroides, Prevotella and Ruminococcus [56]. In terms of function, it is indicated that drivers of each of the three enterotypes use different routes to generate energy from substrates available in the colon. Bacteroides seem to derive energy primarily from carbohydrates and proteins through fermentation, Prevotella is a known mucin degrader and Ruminococcus is linked to both mucin and sugar [56].

Numerous studies have shown that colonization of the GI tract in infants depends upon delivery mode and that the vagina has evolved to serve the fundamental inoculum for all mammals [57]. If a baby is exposed to vaginal microbes during birth, its initial gut bacteria will consist dominantly of Lactobacillus and Prevotella spp [58]. The bacteria, acquired from their mother’s vaginal canal, can be found in the skin and mouth and the meconium of the baby. Many babies are not exposed to their mother’s vaginal flora, due to the cesarean section-birth method (C-section). In contrast to vaginally delivered babies, those delivered by C-section accommodate bacterial communities that resemble bacteria of the skin: Staphylococcus, Corynebacterium and Propionibacterium spp [59]. In early childhood, the initial strains of GI bacteria are outcompeted by other bacterial strains, of a less certain origin, which rapidly increase in diversity and shift in response to dietary changes and/or illness [60, 61]. During early childhood, when peas and other plant-derived foods are introduced, the bacterial phyla of the GI tract changes and Firmicutes and Bacteroidetes are now dominant [62]. Microbial community can change, but the changes are now of a much slower rate than in early childhood and with unknown effects on health. The mentioned data and the development of the GI tract colonization in infants and early childhood can be seen in Table 1.

PREDOMINANT BACTERIAL COMMUNITES Vaginal birth C-section Firmicutes
Prevotella spp.
Propionibacterium spp

Table 1.

Development of the GI tract colonization in infants and early childhood

Children from different parts of the world have different gut microbiota (for example Burkina Faso and Italy) [63], and when it comes to elderly, their GI tract microbiota is substantially different than in young adults [64]. According to Zoetendal et al., the gut microbiota composition of spouses showed the least degree of species similarity, while siblings showed increased degree of similarity in species make up [65].

The gut microbiota acts as a metabolic organ via production of short chain fatty acids and vitamins and it contributes to the barrier effect by preventing colonisation by pathogens. Recent studies have shown that a modulation of a gut microbiota using prebiotics increases epithelial barrier integrity by increasing expression of tight junction proteins [66]. The gut microbiota also helps to shape and maintain normal mucosal immunity.

The human gut microbiome consists of 150x more genes than the human genome [67]. In 2010, initiative called Meta-HIT (Metagenomics of the Human Intestinal Tract) published a catalogue of the microbial genomes strained from 124 faecal samples. The results found that the gene set was approximately 150 times larger than the human gene complement with 3,3 million different microbial genes [68]. Recent studies have shown that the intestine is home to specialized dendrytic cells, whose function is to induce a highly tolerogenic response from T and B cells, through induction of regulatory T cells and secretion of IgA [69]. Activated immune cells, such as mucosal dendrytic cells, constantly sample luminal microbial antigens and present them to adaptive immune cells [70]. There are three main ways by which flagellin from commensal microbes may play a role in IBD. Flagellin from commensal microbes may cross the altered epithelial barrier that occurs in IBD. Such flagellin can, via Toll-like receptor 5 (TLR5), induce the epithelium to secrete cytokines that recruit polymorphonuclear neutrophils (PMN) [71]. Such cytokines may promote adaptive immunity and/or, alternatively, flagellin may activate dendritic cells and directly promote adaptive immune immunity. Flagellin is also targeted by the CD-associated adaptive immune response [71].

In healthy hosts the pro-inflammatory pathways associated with TLR and NLR are suppressed by inhibitory molecules of both human and bacterial origin, such as COX-2 inhibitors, NF-κβ inhibitor, IL-10, TGF-β, IFN-α/β etc. [72, 73]. A disruption of this homeostasis threatens the state of immune tolerance and may result in gut inflammation. How the host tolerates resident bacteria whilst being able to mount an effective inflammatory response to invading pathogens is still not fully understood.

Gut microbiota and activity in IBD patients are proven to be abnormal. IBD patients are characterized by a reduced abundance of dominant members of the gut microbiota. According to Frank et al., mucosal biopsies taken from CD and UC patients showed reduced abundance of Firmicutes and Bacteroidetes and a concomitant increase of Proteobacteria and Actinobacteria, compared to non-IBD control [74]. As a consequence of this dysbiosis, the relative abundance of Enterobacteriaceae was increased in IBD patients compared to healthy control [75, 76]. Significantly lower counts of Bifidobacterium populations were found in rectal biopsies of patients with UC [77]. Study performed by Macfarlane et al. showed that Clostridium leptum (Firmicutes) is less abundant in fecal samples of CD patients (Table 2) [77].

Clostridium and Bacteroides species are the cardinal producers of short chain fatty acids (SCFA) in the human colon [66]. There were decreased SCFA concentrations found in fecal samples of IBD patients, which could be explained by decreased clostridia of groups IV and XIVa (a broad phylogenetic classification comprised of several genera and species of gram positive bacteria). Among the SCFA produced upon carbohydrate fermentation, butyrate has an important role as a major source of energy for colonic epithelial cells, an inhibitor of pro-inflammatory cytokine expression in the intestinal mucosa and an inductor of production of mucin and antimicrobial peptides, thus strengthening epithelial barrier [66, 78]. A decrease of butyrate levels could be involved in the increased inflammatory state characteristic of IBD. Stimulation of butyric acid production could be achieved through repopulation of clostridial clusters IV and XIVa, or even through probiotic therapy with lactic acid bacteria [79]. Some evidence has indicated a promising therapeutic effect of pro, pre and synbiotics in IBD.

↑Proteobacteria, Actinobacteria
↓Clostridium leptem (Firmicutes) in CD
↓Bifidobacterium in UC

Table 2.

Most abundant bacterial communities in healthy human large intestine and its alterations in IBD

Paneth cells of the small intestine also have an important role in the human gut microbiota, as they are a source of α defensins 5 and 6, which may regulate and maintain microbial balance in the intestinal lumen. The α defensins 5 and 6 are efficacious against Enterobacteriaceae and Bacteroides vulgatus and studies have shown their levels are increased in chronic inflammatory conditions [80, 81]. In association with ileal CD, they are significantly reduced, particularly in patients with NOD-2 mutations. Colonic CD (but not UC) is associated with β defensins 2 and 3, which are secreted by leukocytes and epithelial cells of many kinds [82].

As explained above, it is a widely accepted hypothesis that the bacteria play an important role in the pathogenesis of IBD. There are several ways in which the microbiota might be linked to IBD. The microbiota as a whole could act as a surrogate pathogen, or specific members of the microbiota could be overt pathogens.

It remains unclear whether the altered gut microbiota composition is a cause of the disease or a consequence of the inflammatory state, but it is most likely that microbial dysbiosis and lack of beneficial bacteria, together with genetically predisposed increased epithelial permeability, bacterial translocation into the lamina propria, defective innate immunity and loss of tolerance to the resident microbiota eventually lead to IBD.


3. Conclusion

Chronic intestinal inflammation in inflammatory bowel disease develops under the influence of environmental triggers in genetically susceptible individuals with an altered immune response. The role of the intestinal microbiota in the pathogenesis of IBD still remains unclear, but even though some enteric bacteria are detrimental and some are protective, their involvement in the pathogenesis of IBD is unquestionable. Table 3 lists main factors associated with IBD development, including known differences between UC and CD ethiopathogenesis.

Since we currently lack complete understanding of the mechanisms leading to the disease, this topic remains to be exceedingly interesting and enigmatic and most certainly a challenging clinical entity that yet remains to be further investigated and unraveled.

ENVIRONMENTAL FACTORS ‘westernization of lifestyle’
Smoking (protective in UC , detrimental in CD)
Use of antibiotics
Use of NSAIDs
GENETIC PREDISPOSITION Major histocompatibility complex region (6p21) mutations in genes encoding interleukin (IL)-10 receptor and the IL-10 cytokine
genes mediating epithelial defense function NOD2 mutations
ATG16L1 expression
HOST IMMUNE RESPONSE Higher level of TLR2, 4 and CD 40, followed by increased production of IL-12 and IL-6

Activation of NF-κB

Expression of IL-1β, TNF, IL-6, IL-8, ICAM1, CD 40, CD 80 and other chemokines, adhesion molecules and co-stimulatory molecules
Innate immune responses
Adaptive immune responses atypical TH2 response, mediated by NK-T cells that secrete IL-13 and IL-5 predominantly TH1 and TH17
(mediated by IL 12 and IL17)
*see table 1 and 2 for further information
microbiota as a whole acts as a surrogate pathogen, or specific members of the microbiota could be overt pathogens*

Table 3.

Interaction of environmental factors, genetic predisposition, host immune response and intestinal microbiota, main factors associated with CD and UC ethiopathogenesis


  1. 1. Wehkamp J, Stange F E. Paneth’s Disease. Journal of Crohn's & colitis 2010;4(5): 523-531.
  2. 2. Nell S, Suerbaum S, Josenhans C. The Impact of the Microbiota on the Pathogenesis of IBD: Lessons from Mouse Infection Models. Nature Reviews Microbiology 2010;8(8):564-577.
  3. 3. Sartor RB. Therapeutic Manipulation of the Enteric Microflora in Inflammatory Bowel Diseases: Antibiotics, Probiotics, and Prebiotics. Gastroenterology 2004;126(6):1620-1633.
  4. 4. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, Scholmerich J, Sartor RB. Different Subsets of Enteric Bacteria Induce and Perpetuate Experimental Colitis in Rats and Mice. Infect Immun 2001;69(4):2277-2285.
  5. 5. Hoentjen F, Harmsen HJM, Braat H, Torrice CD, Mann BA, Sartor RB, Dieleman LA. Antibiotic with a Selective Aerobic or Anaerobic Spectrum have Different Therapeutic Activities in Various Regions of the Colon in Interleukin 10 Gene Deficient Mice. Gut 2003;52(12):1721-1727.
  6. 6. Loftus EV Jr. Clinical Epidemiology of Inflammatory Bowel Disease: Incidence, Prevalence, and Environmental Influences. Gastroenterology 2004;126(6):1504-1517.
  7. 7. Hanauer BS, Inflammatory Bowel Disease: Epidemiology, Pathogenesis, and Therapeutic Opportunities, Inflamm Bowel Dis.2006;12(1):3-9.
  8. 8. Shaw SY, Blanchard JF, Bernstein CN., Association Between the Use of Antibiotics in the First Year of Life and Pediatric Inflammatory Bowel Disease. Am J Gastroenterol. 2010;105(12):2687-2692.
  9. 9. Berg DJ Zhang J, Weinstock JV, Ismail HF, Earle KA, Alila H, Pamukcu R, Moore S, Lynch RG. Rapid Development of Colitis in NSAID Treated IL-10 Deficient Mice. Gastroenterology;2002 123(5):1527-1542.
  10. 10. Brinar M, Vermeire S, Cleynen I, Lemmens B, Sagaert X, Henckaerts L, Van Assche G, Geboes K, Rutgeerts P, De Hertogh G. Genetic Variants in Autophagy-related Genes and Granuloma Formation in a Cohort of Surgically Treated Crohn’s Disease Patients. J Crohn’s Colitis 2012;6(1):43-50
  11. 11. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. , Epidemiology and Natural History of Inflammatory Bowel Diseases. Gastroenterology 2011;140(6):1785-1794.
  12. 12. Bach JF. The Effect of Infections on Susceptibility to Sutoimmune and Allergic Diseases. N Engl J Med 2002;347(12):911-920.
  13. 13. Sinčić Mijandrušić B, Vucelić B, Peršić M, Brnčić N, Eržen Jurišić D, Radaković B, Mićović V, Štimac D., Incidence of Inflammatory Bowel Disease in Primorsko-goranska County, Croatia, 2000-2004: A prospective Population-based Study. Scand J Gastroenterol. 2006;41(4):437-44.
  14. 14. Newman B, Siminovitch KA. Recent Advances in the Genetics of Inflammatory Bowel Disease. Curr Opin Gastroenterol. 2005;21(4):401-7.
  15. 15. Judy H. Cho, Steven R. Brant. Recent Insights Into the Genetics of Inflammatory Bowel Disease. Gastroenterology 2011;140(6):1704-1712.
  16. 16. Brant SR. Update on the Heritability of Inflammatory Bowel Disease: The Importance of Twin Studies. Inflammatory Bowel Diseases 2011;17(1):1-5 .
  17. 17. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor. N Engl J Med 2009;361(21):2033-2045.
  18. 18. Glocker EO, Frede N, Perro M, Sebire N, Elawad M, Shah N, Grimbacher B. Infant Colitis - It's in the Genes. The Lancet 2010; 376(9748) 1272
  19. 19. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the Interleukin-10 Receptor. Annu Rev Immunol. 2001;19:683-765.
  20. 20. Hugot JP, Chamaillard M, Zouali H, Lesage S, CeÂzard JP, Belaiche J, Almerk S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macrykk J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599-603.
  21. 21. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A Frameshift Mutation in NOD2 Associated with Susceptibility to Crohn's Disease. Nature 2001;411(6837):603-606.
  22. 22. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential Effects of NOD2 Variants on Crohn's Disease Risk and Phenotype in Diverse Populations: A Metaanalysis. Am J Gastroenterol. 2004;99(12):2393-404.
  23. 23. Ahuja V, K Tandon R. Inflammatory Bowel Disease in the Asia–Pacific Area: A Comparison with Developed Countries and Regional Differences. Journal of Digestive Diseases 2010;11(3):134–147.
  24. 24. Gregorieff A, Clevers H. Wnt Signaling in the Intestinal Epithelium: from Endoderm to Cancer. Genes Dev 2005; 19(8):877-890.
  25. 25. Barker N. The Canonical Wnt/beta-Catenin Signaling Pathway. Methods Mol Biol 2008;468:5-15.
  26. 26. Crosnier C, Stamataki D, Lewis J. Organizing Cell Renewal in the Intestine: Stem Cells, Signals and Combinatorial Control. Nat Rev Genet 2006;7(5):349-59.
  27. 27. Wehkamp J, Schmid M, Stange EF. Defensins and Other Antimicrobial Peptides in Inflammatory Bowel Disease. Curr Opin Gastroenterol 2007;23(4):370-378.
  28. 28. Ericksen B, Wu Z, Lu W, Lehrer RI. Antibacterial Activity and Specificity of the Six Human α-Defensins. Antimicrob Agents Chemother. 2005;49(1):269–275.
  29. 29. Klotman ME, Chang TL. Defensins in Innate Antiviral Immunity. Nat Rev Immunol 2006;6(6) 447-456.
  30. 30. Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, Ogunbiyi O, Nuñez G, Keshav S. Crohn's Disease and the NOD2 Gene: A Role for Paneth Cells. Gastroenterology. 2003;125(1):47-57.
  31. 31. Rosenstiel P, Fantini M, Bräutigam K, Kühnbacher T, Waetzig GH, Seegert D, Schreiber S. Gastroenterology. 2003;124(4):1001-1009.
  32. 32. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell RA. Nod2-Dependent Regulation of Innate and Adaptive Immunity in the Intestinal Tract. Science. 2005;307(5710):731-734.
  33. 33. Fishbein T, Novitskiy G, Mishra L, Matsumoto C, Kaufman S, Goyal S, Shetty K, Johnson L, Lu A, Wang A, Hu F, Kallakury B, Lough D, Zasloff M. NOD2-Expressing Bone Marrow-Derived Cells Appear to Regulate Epithelial Innate Immunity of the Transplanted Human Small Intestine. Gut. 2008;57(3):323-330.
  34. 34. Levine B, Deretic V. Unveiling the Roles of Auotphagy in Innate and Adaptive Immunity. Nat Rev Immunol 2007;7(10):767-777.
  35. 35. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin HW 4th. A Key Role for Autophagy and the Autophagy Gene Atg16l1 in Mouse and Human Intestinal Paneth Cells. Nature. 2008;456(7219):259-263.
  36. 36. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ. Genome-Wide Association Defines More than 30 Distinct Susceptibility Loci for Crohn's Disease. Nat Genet. 2008;40(8):955-962.
  37. 37. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H, Lees CW, Khawaja SA, Bagnall R, Burke DA, Todhunter CE, Ahmad T, Onnie CM, McArdle W, Strachan D, Bethel G, Bryan C, Lewis CM, Deloukas P, Forbes A, Sanderson J, Jewell DP, Satsangi J, Mansfield JC; Wellcome Trust Case Control Consortium, Cardon L, Mathew CG. Sequence Variants in the Autophagy Gene IRGM and Multiple Other Replicating Loci Contribute to Crohn's Disease Susceptibility. Nat Genet. 2007;39(7):830-832.
  38. 38. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Wu Data L, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene. Science 2006;314(5804):1461- 1463.
  39. 39. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB. A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-risk Genes. Am J Hum Genet. 2007;80(2):273-290.
  40. 40. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-Wide Meta-Analysis Increases to 71 the Number of Confirmed Crohn's Disease Susceptibility Loci. Nat Genet. 2010;42(12):1118-1125.
  41. 41. Sartor RB, Hoentjen F. Proinflammatory Cytokines and Signaling Pathways in Intestinal Innate Immune Cells. Mucosal Immunology London: Elsevier Academic Press; 2005. pp. 681–701.
  42. 42. Siew C Changing Epidemiology and Future Challenges of Inflammatory Bowel Disease in Asia. Intestinal Research 2010;8(1)1-8.
  43. 43. Reaves TA, Chin AC, Parkos CA. Neutrophil Transepithelial Migration: Role of Toll-like Receptors in Mucosal Inflammation. Mem Inst Oswaldo Cruz. 2005;100(1):191-198.
  44. 44. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ. Characteristics of Intestinal Dendritic Cells in Inflammatory Bowel Diseases. Gastroenterology. 2005;129(1):50-65.
  45. 45. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of Commensal Microflora by Toll-Like Receptors is Required for Intestinal Homeostasis. Cell. 2004;118(2):229-241.
  46. 46. Neurath MF, Pettersson S, Meyer zum Büschenfelde KH, Strober W. Local Administration of Antisense Phosphorothioate Oligonucleotides to the p65 Subunit of NF-kappa B Abrogates Established Experimental Colitis in Mice. Nat Med. 1996;2(9):998-1004.
  47. 47. Cario E, Podolsky DK. Differential Alteration in Intestinal Epithelial Cell Expression of Toll-Like Receptor 3 (TLR3) and TLR4 in Inflammatory Bowel Disease. Infect Immun. 2000;68(12):7010-7017.
  48. 48. Barnias G, Martin CIII, Mishina M, Ross WG, Rivera Nieves J, Marini M, Cominelli F. Proinflammatory Effects of TH2 Cytokines in a Murine Model of Chronic Small Intestinal Inflammation. Gastroenterology 2005;128(3):654-666.
  49. 49. Kolls JK, Linden A. Interleukin -17 Family Members and Inflammation. Immunity 2004;21(4):467-476.
  50. 50. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased Expression of IL-17 in Inflammatory Bowel Disease. Gut 2003;52(1):65-70.
  51. 51. Strober W, Fuss IJ. Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases. Gastroenterology 2011;140(6):1756-1767.
  52. 52. Fuss IJ Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W. Nonclassical CD1d-Restricted NK T Cells that Produce IL-13 Characterize an Atypical Th2 Response in Ulcerative Colitis. J Clin Invest. 2004;113(10):1490–1497.
  53. 53. Liu Z, Geboes K, Heremans H, Overbergh L, Mathieu C, Rutgeerts P, Ceuppens JL. Role of Interleukin-12 in the Induction of Mucosal Inflammation and Abrogation of Regulatory T cell Function in Chronic Experimental Colitis. European Journal of Immunology 2001; 31(5):1550-1560.
  54. 54. Smythies LE, Shen R, Bimczok D, Novak L, Clements RH, Eckhoff DE, Bouchard P, George MD, Hu WK, Dandekar S, Smith PD. Inflammation anergy in human intestinal macrophages is due to Smad-induced IkappaBalpha expression and NF-kappaB inactivation..J Biol Chem 2010;285(25):19593–19604.
  55. 55. Jung C,Hugot JP, Barreau F. Peyer's Patches: The Immune Sensors of the Intestine. International Journal of Inflammation 2010 Article ID 823710, 12 pages, doi:10.4061/2010/823710.
  56. 56. Arumugam M, Raes J,nPelletier E, Le Paslier D, Yamada T, Mende1 DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen BH, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Dore J, MetaHIT Consortium, Weissenbach J, Ehrlich SD, Bork P Enterotypes of the human gut microbiome. Nature 2011;473:174–180.
  57. 57. Dominguez-Bello MG, Blaser M, Ley RE, Knight R. Development of the Human Gastrointestinal Microbiota and Insights From High -Throughput Sequencing. Gastroenterology 2011;140(6):1713-1719.
  58. 58. Domínguez-Bello MG, Costtello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R. Delivery Mode Shapes the Acquisition and Structure of the Initial Microbiota Across Multiple Body Habitats in Newborns. Proc Natl Acad Sci U S A. 2010;107(26):11971–11975.
  59. 59. Mackie RI, Sghir A, Gaskins HR. Developmental Microbial Ecology of the Neonatal Gastrointestinal Tract. Am J Clin Nutr. 1999;69(5):1035–1045.
  60. 60. Vaishampayan PA, Kuehl JV, Froula JL, Morgan JL, Ochman H, Pilar Francino M. Comparative Metagenomics and Population Dynamics of the Gut Microbiota in Mother and Infant. Genome Biol Evol. 2010;6(2):53–66.
  61. 61. Matsumiya Y, Kato N, Watanabe K, Kato H.. Molecular Epidemiological Study of Vertical Transmission of Vaginal Lactobacillus Species from Mothers to Newborn Infants in Japanese, by Arbitrarily Primed Polymerase Chain Reaction. J Infect Chemother. 2002;8(1):43–49.
  62. 62. Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, Angenent LT, Ley RE. Microbes and Health Sackler Colloquium: Succession of Microbial Consortia in the Developing Infant Gut Microbiome. Proc Natl Acad Sci U S A. 2011;108(1):4578–4585
  63. 63. Filippo C, Cavalieri D, Di Paola M, Ramazzotti M,Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of Diet in Shaping Gut Microbiota Revealed by a Comparative Study in Children from Europe and Rural Africa. Proc Natl Acad Sci U S A. 2010;107(33):14691–14696
  64. 64. Rajilic-Stojanovic M, Heilig HG, Molenaar D, Kajander K, Surakka A, Smidt H, de Vos WM. Development and Application of the Human Intestinal Tract Chip, a Phylogenetic Microarray: Analysis of Universally Conserved Phylotypes in the Abundant Microbiota of Young and Elderly Adults. Environ Microbiol. 2009;11(7):1736–1751.
  65. 65. Zoetendal EG, Akkermans ADL, Akkermans-van Vliet WM, de Visser JAGM, de Vos WM. The Host Genotype Affects the Bacterial Community in the Human Gastronintestinal Tract. Microb Ecol Health Dis. 2001;13(3):129-134.
  66. 66. Fava F., Danese S. Intestinal Microbiota in Inflammatory Bowel Disease: Friend of Foe? World J Gastroenterol. 2011;17(5):557-566.
  67. 67. Baoli Zhu, Xin Wang, Lanjuan Li. Human Gut Microbiome: The Second Genome of Human Body. Protein Cell 2010;1(8):718-725.
  68. 68. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A Human Gut Microbial Gene Catalogue Established By Metagenomic Sequencing. Nature 2010;464(7285):59-65.
  69. 69. Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F. A Functionally Specialized Population of Mucosal CD103+ DCs Induces Foxp3+ Regulatory T Cells via a TGF-Beta and Retinoic Acid-Dependent Mechanism. J Exp Med. 2007;204(8):1757-1764.
  70. 70. Tezuka H, Abe Y, Iwata M, Takeuchi H, Ishikawa H, Matsushita M, Shiohara T, Akira S, Ohteki T. Regulation of IgA Production by Naturally Occurring TNF/iNOS-Producing Dendritic Cells. Nature. 2007;448(7156):929-933
  71. 71. Gewirtz AT. TLRs in the Gut. III. Immune Responses to Flagellin in Crohn's Disease: Good, Bad, or Irrelevant? Am J Physiol Gastrointest Liver Physiol 2007;292(3):706-710.
  72. 72. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, Rao AS, Madara JL. Prokaryotic Regulation of Epithelial Responses by Inhibition of IkappaB-alpha Ibiquitination. Science. 2000;289(5484):1560-1563.
  73. 73. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, Xu R, Inoue H, Arditi M, Dannenberg AJ. Cox-2 is Regulated by Toll-Like Receptor-4 (TLR4) Signaling: Role in Proliferation and Apoptosis in the Intestine. Gastroenterology. 2006;131(3):862-877.
  74. 74. Frank DN, St. Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-Phylogenetic Characterization of Microbial Community Imbalances in Human Inflammatory Bowel Diseases. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(34):13780–13785.
  75. 75. Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van Zanten SJ. Differences Between Tissue-Associated Intestinal Microfloras of Patients with Crohn's Disease and Ulcerative Colitis. J Clin Microbiol. 2006;44(11):4136-4141.
  76. 76. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P. Reduced Diversity of Faecal Microbiota in Crohn's Disease Revealed by a Metagenomic Approach. Gut. 2006;55(2):205-211.
  77. 77. Macfarlane S, Furrie E, Cummings JH, Macfarlane GT. Chemotaxonomic Analysis of Bacterial Populations Colonizing the Rectal Mucosa in Patients With Ulcerative Colitis. Clin Infect Dis. 2004;38(12):1690-1699
  78. 78. Vanhoutvin SA, Troost FJ, Hamer HM, Lindsey PJ, Koek GH, Jonkers DM, Kodde A, Venema K, Brummer RJ. Butyrate-Induced Transcriptional Changes in Human Colonic Mucosa. PLoS One. 2009;4:e6759. doi:10.1371/journal.pone.0006759
  79. 79. Duncan SH, Louis P, Flint HJ. Lactate-Utilizing Bacteria, Isolated from Human Feces, that Produce Butyrate as a Major Fermentation Product. Appl Environ Microbiol. 2004;70(10):5810-5817.
  80. 80. Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced Mucosal Antimicrobial Activity in Crohn's Disease of the Colon. Gut. 2007;56(9):1240-1247.
  81. 81. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schäffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P. NOD2 (CARD15) Mutations in Crohn's Disease are Associated with Diminished Mucosal Alpha-Defensin Expression. Gut. 2004;53(11):1658-1664.
  82. 82. Wehkamp J, Harder J, Weichenthal M, Mueller O, Herrlinger KR, Fellermann K, Schroeder JM, Stange EF. Inducible and Constitutive Beta-Defensins are Differentially Expressed in Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis. 2003;9(4):215-223.

Written By

Ana Brajdić and Brankica Mijandrušić-Sinčic

Submitted: May 19th, 2012 Published: December 5th, 2012